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Background
The Toxicology Investigator’s Consortium  (ToxIC) 
database was created in 2010 by the American 
College of Medical Toxicology (ACMT) to compile data 
recorded by  medical toxicologists in both inpatient and 
outpatient settings. In January, 2017 the data field for 
transgender (and if trans gender, male-to-female or 
female-to-male) was added to the ToxIC form. Little  
is known regarding self-harm poisonings  within the 
transgender population. The aim of this study was to 
review toxicology consultations around poisonings in 
transgender patients, and provide descriptive data  
in trends among those within this  demographic. 
Methods
In this study, a retrospective ToxIC database review of 
cases in which the patient identified as transgender 
was done from January 2017–June 2019 and 
descriptive demographics reported.
Results
The database query identified 113 transgender 
patients. Fifty-one (45.1%) of the 113 were between  
13–18 years old and 60 (53.1%) were aged 19–65 
years old. There was 1 patient identified as being 
between 7–12 years old and 1 between 66–89 years 
old. The primary reason for the encounter for 97 of the 
patients was for intentional pharmaceutical ingestion, 
and of these encounters, 85 (87.6%) were classified as 
intentional pharmaceutical use intended for self-harm.
Among the 51 patients aged 13–18, 46 (90.2%) 
identified attempt at self-harm with pharmaceutical as 
primary reason for encounter. Within the 60 patients 
aged 19–65, 37 (61.7%) identified primary reason for 
encounter as attempted self-harm with pharmaceutical.
Excluding missing data, of the 113 patients, 41 (36.3%) 
were recorded as male-to-female, 68 (60.2%) female-
to-male and 3 (2.7%) as gender-nonconforming. In the 
41 male-to-female transgender patients, 28 (68.3%) 
identified the encounter was for intentional self-harm 
with a pharmaceutical agent. Of the 68 female-to-male 
transgender patients 53 (77.9%) identified the primary 
reason for encounter as intent for self-harm with a 
pharmaceutical agent. 
Conclusions
Most toxicological consults in this cohort of trans-
gender patients were for intentional pharmaceutical 
use intended for self-harm. In this small sample there 
were some age and transition differences in prevalence. 
Data describing sex and gender-specific differences in 
types of exposures/ingestions, as well as outcomes, 
may inform poisoning prevention practices as well as 
sex and gender-based management of patients. 
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